Private Equity Gp I, Llc So... Net Worth

The estimated Net Worth of Private Equity Gp I, Llc So... is at least 41.9 千$ dollars as of 5 May 2020. Private So owns over 155,000 units of Lyra Therapeutics stock worth over 41,850$ and over the last 5 years Private sold LYRA stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Private So LYRA stock SEC Form 4 insiders trading

Private has made over 1 trades of the Lyra Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Private bought 155,000 units of LYRA stock worth 2,480,000$ on 5 May 2020.

The largest trade Private's ever made was buying 155,000 units of Lyra Therapeutics stock on 5 May 2020 worth over 2,480,000$. On average, Private trades about 155,000 units every 0 days since 2020. As of 5 May 2020 Private still owns at least 155,000 units of Lyra Therapeutics stock.

You can see the complete history of Private So stock trades at the bottom of the page.

Insiders trading at Lyra Therapeutics

Over the last 5 years, insiders at Lyra Therapeutics have traded over 0$ worth of Lyra Therapeutics stock and bought 19,620,470 units worth 85,899,322$ . The most active insiders traders include Advisors Llcperceptive Life...、Edward T Anderson、Gp, Llcdamore Richard Anort.... On average, Lyra Therapeutics executives and independent directors trade stock every 76 days with the average trade being worth of 311,619$. The most recent stock trade was executed by Harlan Waksal on 10 November 2023, trading 25,000 units of LYRA stock currently worth 74,000$.

What does Lyra Therapeutics do?

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Complete history of Private So stock trades at Lyra Therapeutics

Lyra Therapeutics executives and stock owners

Lyra Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Maria Palasis Ph.D.,
  CEO, Pres & Director
• R. Donald Elsey MBA,
  Advisor
• Dr. Robert Richard Ph.D.,
  Sr. VP of R&D
• Pamela E. Nelson,
  Sr. VP of Regulatory Affairs
• Vineeta Belanger Ph.D.,
  Sr. VP of Clinical Affairs
• Corinne Noyes,
  Sr. VP of Commercial Strategy & Market Devel.
• Ray Knox,
  VP of Operations
• Jason Cavalier,
  Chief Financial Officer
• Dr. Carmichael S. Roberts Jr., Ph.D.,
  Co-Founder
• Dr. Harlan W. Waksal M.D.,
  Exec. Chairman
• Maria Palasis,
  President & CEO
• Carmichael Roberts,
  10% owner
• Robert Langer,
  Director
• Advisors Llcperceptive Life...,
  
• George M Whitesides,
  Director
• Venture Management Co. V, L...,
  
• R Don Elsey,
  CFO, Treasurer & Secretary
• Gp, Llcdamore Richard Anort...,
  
• Private Equity Gp I, Llc So...,
  
• Laura Edgerly Pflug,
  See Remarks
• Corinne Noyes,
  See Remarks
• Michael Seth Altman,
  
• Venture Management Co Iv Ll...,
  
• Advisors Llcedelman Joseph ...,
  
• Jason Cavalier,
  Chief Financial Officer
• Robert E. Richard,
  SVP, Technical Operations
• Pamela E. Nelson,
  SVP, Regulatory Affairs
• Harlan Waksal,
  Executive Chair
• Richard Nieman,
  Chief Medical Officer
• John E Bishop,
  Chief Technology Officer
• C Ann Merrifield,
  
• James R Tobin,
  
• Nancy Lynn Md Snyderman,
  
• Konstantin Poukalov,
  
• Edward T Anderson,
  
• W Bradford Smith,